Table 1

CpGs associated with cross-sectional HbA1c at FDR of <20% in the EDC study

IDChrLocationCpG positionGene symbolLocation relative to geneβ per 1% HbA1cSEP valuebacon-adjusted FDR*
cg196930311Open Sea145 441 552TXNIP3′UTR0.0160.00252.67E-100.0001
cg2153433017S. Shore80 209 281CSNK1DBody0.0090.00141.15E-090.0001
cg218577242Open Sea231 523 609n/aIntergenic−0.0050.00103.31E-070.0462
cg0382773910Open Sea75 401 754MYOZ1TSS15000.0040.00078.69E-070.1506
cg142095625Open Sea177 880 534COL23A1Body−0.0060.00138.93E-070.0800
cg1922560211N.Shelf75 269 316n/aIntergenic−0.0030.00072.18E-060.0800
cg276299862Open Sea219 585 157TTLL45′UTR−0.0030.00072.23E-060.1320
cg060538446Open Sea3 870 115n/aIntergenic−0.0030.00072.83E-060.1320
cg242369352Open Sea20 690 701n/aIntergenic−0.0040.00093.07E-060.1320
cg1842265414Open Sea23 905 273MYH7TSS1500−0.0030.00063.40E-060.1325
cg1106939512N.Shore53 272 002n/aIntergeniIc−0.0040.00083.59E-060.1325
cg2151346312Open Sea131 076 481n/aIntergenic−0.0020.00043.80E-060.1325
cg172388305Open Sea76 256 017CRHBPBody−0.0050.00114.34E-060.1325
cg140513365S.Shelf149 515 317PDGFRBBody−0.0040.00084.83E-060.1325
cg031677126Open Sea83 587 490n/aIntergenic−0.0050.00105.71E-060.1325
cg186400985Open Sea9 888 660LOC285692Body−0.0040.00099.60E-060.1325
cg098473251Open Sea4 842 442AJAP13′UTR−0.0040.00091.04E-050.1339
cg0990511719Open Sea47 454 619ARHGAP35Body−0.0040.00091.05E-050.1410
cg0315685113Open Sea88 675 293n/aIntergenic−0.0060.00131.15E-050.1506
  • Results of linear models adjusted for type 1 diabetes duration, sex, pack years of smoking, estimated cell type composition variables, and plate/run indicator, well position, GCT bisulfite score, DNA extraction method, study visit of DNA collection, first two principal components of ancestry from genotyping arrays, and two surrogate variables from sva, sorted by ascending p value.

  • *Bolded rows are significant at the Bonferroni-adjusted threshold, p<7.3×10−8.

  • CpG, 5′-cytosine-phosphate-guanine-3′; CSNK1D, Casein Kinase 1 Isoform Delta; EDC, Epidemiology of Diabetes Complications; FDR, false discovery rate; n/a, not applicable; TXNIP, Thioredoxin-Interacting Protein.